A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BRII-297 in Healthy Adult Subjects
Latest Information Update: 29 Mar 2024
At a glance
- Drugs BRII-297 (Primary)
- Indications Anxiety; Depressive disorders; Postnatal depression
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Brii Biosciences
Most Recent Events
- 22 Mar 2024 According to a Brii Biosciences media release, company expected data from this trial by the second half of 2024.
- 17 Jan 2024 Status changed from recruiting to completed.
- 01 Jun 2023 Status changed to recruiting, according to a Brii Biosciences media release.